–CV disease is the top killer but pharma is pulling back on developing new drugs. Although cardiovascular disease is the number one cause of death in the world fewer cardiovascular drugs are under development now than in the past, according to a study published in JACC: Basic to Translational Science. Thomas Hwang and colleagues at…
Can Personalized Medicine And An Adaptive Trial Design Salvage This Hard Luck Drug?
December 4, 2013 by Leave a Comment
Arca Biopharma today announced that it had received FDA clearance to start a phase 2B/3 trial of its novel beta-blocker, Gencaro (bucindolol) for the prevention of atrial fibrillation in patients with heart failure. The GENETIC-AF trial has all the hallmarks of the modern era: the drug will only be tested in patients with a genetic variation that the…
Recent Comments